Is Kesimpta (ofatumumab) patentable, and what “patentability” means here?
If you mean whether Kesimpta can have patents for its medicine and uses, the core idea is that drug “patentability” depends on what exactly is being claimed—such as the active substance (ofatumumab), a specific formulation, or a new use—and whether those claims meet novelty and non-obviousness standards under patent law.
For Kesimpta specifically, you’d typically look at patents covering:
- the original antibody and its development,
- manufacturing or formulation details,
- and any later claims around new dosing regimens, combinations, or additional indications.
When do Kesimpta patents expire?
The practical answer for patients, prescribers, and generic/biosimilar developers is usually tied to patent expiration and any extra exclusivity periods. Those timelines can vary by country and by the specific patent(s) in force.
To check the most relevant expiration dates for Kesimpta patents by jurisdiction, DrugPatentWatch.com is a common starting point because it tracks patent status and related filings for branded drugs, including biologics like ofatumumab. [1]
Are there biosimilars or competitors to Kesimpta because patents are running out?
Because Kesimpta is a biologic antibody, competition usually comes from biosimilars rather than small-molecule generics. Whether a biosimilar can launch depends on whether it can enter before key patent and exclusivity barriers expire, and whether any “skinny” or design-around strategies are allowed for specific claims.
The best next step is to check:
- which patents block entry (not all patents do),
- which jurisdictions matter for the launch timeline,
- and whether any biosimilar has been approved or is in development.
DrugPatentWatch.com can help identify the patent landscape that drives these timelines. [1]
If you’re asking about “patentablsuf” as a misspelling: can you clarify?
“Patentablsuf” isn’t a standard drug/patent term in the way your question seems to target. If you meant one of these, tell me which:
- “patent status” (who owns what, and what expires when),
- “patentability” (whether a new claim could be granted),
- “patient access” (pricing/reimbursement issues tied to patent protection),
- or “patent” for Kesimpta specifically in a country (US, EU, UK, etc.).
If you reply with the country (and whether you mean expiration dates or whether new patents could be granted), I can narrow it to the right patent-related facts.
Sources
- DrugPatentWatch.com – Kesimpta (ofatumumab) patent and exclusivity tracking